WEBULL
News
SLDB
5.87
0.00%
0.00
SOLID BIOSCIENCES TO SHOWCASE PROPRIETARY NEXT-GENERATION CAPSID AAV-SLB101 AND CARDIAC GENE THERAPY PIPELINE AT THE 22ND GLOBAL CARDIOVASCULAR CLINICAL TRIALISTS (CVCT) FORUM
Reuters · 6d ago
Weekly Report: what happened at SLDB last week (1201-1205)?
Weekly Report · 12/08 09:08
Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst
Benzinga · 12/04 20:38
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 12/04 14:21
Solid Biosciences Price Target Announced at $16.00/Share by Needham
Dow Jones · 12/04 12:12
Needham Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $16
Benzinga · 12/04 12:02
Needham starts Solid Biosciences at Buy on opening in DMD market
TipRanks · 12/04 11:50
SOLID BIOSCIENCES INC <SLDB.O>: NEEDHAM INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $16
Reuters · 12/04 11:45
Solid Biosciences initiated with a Buy at Needham
TipRanks · 12/04 11:45
U.S. RESEARCH ROUNDUP-Fiserv, PayPal, UMH Properties
Reuters · 12/04 07:52
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 12/02 21:05
SOLID BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/01 21:05
Solid Biosciences receives Rare Pediatric Disease designation of SGT-212
TipRanks · 12/01 13:15
Solid Biosciences Announces The FDA Grants Rare Pediatric Disease Designation For SGT-212, Its Investigational Gene Therapy For Friedreich's Ataxia
Benzinga · 12/01 13:02
SOLID BIOSCIENCES RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR SGT-212 DUAL ROUTE OF ADMINISTRATION GENE THERAPY FOR FRIEDREICH’S ATAXIA
Reuters · 12/01 13:00
Weekly Report: what happened at SLDB last week (1124-1128)?
Weekly Report · 12/01 09:07
Solid Biosciences management to meet with Citizens JMP
TipRanks · 11/24 19:15
Weekly Report: what happened at SLDB last week (1117-1121)?
Weekly Report · 11/24 09:08
Citizens JMP healthcare analysts hold an analyst/industry conference
TipRanks · 11/18 17:15
Strategic Advancements and Growth Potential: Solid Biosciences’ Buy Rating Validated by Key Partnerships and Regulatory Progress
TipRanks · 11/17 14:15
More
Webull provides a variety of real-time SLDB stock news. You can receive the latest news about Solid Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.